LEXINGTON, Mass. (AP) — Cubist Pharmaceuticals Inc. said Monday it posted $560.3 million in revenue during 2009, up 30 percent from a year earlier and meeting Wall Street forecasts.
The company said U.S. sales of the antibiotic Cubicin, its only marketed product, rose 26 percent to $524 million. It also had $13.8 million in revenue from international sales and $22.5 million in service revenue.
Analysts polled by Thomson Reuters expected revenue of $559.5 million, on average.
Revenue in 2008 totaled $433.6 million.
Fourth-quarter U.S. Cubicin sales rose 23 percent to $147.8 million.
The company said it will release full fourth-quarter and 2009 financial results on Jan. 21.
Shares of Cubist rose 12 cents to $18.90 in morning trading.